A Phase 2 trial showed that patients with PTEN-deficient castration-resistant prostate cancer had improved radiographic progression-free survival when treated with a combination of the hormone therapy drug abiraterone and an AKT blocker.115 Although PTEN biomarker testing has been a consideration for standard therapeutic responses, only a limited number of clinical trials plan to determine PTEN status in relation to the clinical response of tumours with ICIs (more details in Table 3). This evidence concerns the gene AKT1 and neoplasm.